

NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Susan Burke, Account Executive,
Ronald Trahan Associates Inc.,
508.647.9782, ext. 20

New Technology for Breast Cancer Detection in Young Women Featured at Emerging Medical Technology Conference

Premier business development, strategic partnering, and investment meeting for medical technology executives to be held at Sheraton Boston Hotel, Boston, Oct. 24-25, 2002

RAMSEY, N.J., Oct. 22, 2002 – TransScan Medical Ltd. (www.TSCAN.org), developer and manufacturer of Electrical Impedance Scanning (EIS)-based systems for cancer detection, announced today that it will be one of the featured companies at the Medtech Insight conference – ‘Investment in Innovation (In³): A Preview of Early-Stage Medical Technology Companies’ – to be held at the Sheraton Boston Hotel on October 24-25, 2002.

The ‘In³’ conference, organized by Medtech Insight (www.medtechinsight.com), will highlight emerging technologies being developed by some 50 privately held medical technology companies seeking strategic partners and/or investors. The Boston meeting is expected to draw more than 300 senior executives from the investment community and major medical technology, biopharmaceutical, biotech and other companies.

TransScan’s patented core technology, *The T-Scan™ 2000* received FDA clearance as an adjunct to mammography in April 1999 and was hailed by the FDA as “a significant medical device breakthrough” based on its ability to assist radiologists in evaluating ambiguous or equivocal mammography findings.

TransScan President, Dr. Ron Ginor will present the “second generation” *T-Scan™ 2000 ED* and describe the Company’s focus on early detection of breast cancer in women below the recommended age for screening mammography, for whom the only method currently in use is the Clinical Breast Exam (‘CBE’).

While tumors must commonly be fairly large in size (7.5-10 mm) before they are palpable by a CBE and cannot be differentiated as cancerous or benign, the *T-Scan™ 2000 ED* allows physicians to detect a tumor as small as 2 mm in size with a high degree of specificity for malignancy (90-95%). When used in conjunction with CBE, *T-Scan™ 2000 ED* provides a highly effective means of detecting cancer at an early stage.

“We are indeed honored to be a featured participant at this conference. It not only provides an excellent opportunity to present our technology, but I consistently find that Medtech Insight conferences are an excellent platform for cross-pollination of ideas, strategic alliances and, of course, potential funding – in other words, a highly targeted, single source for critical partnering and financing activities,” said Dr. Ginor.

#####